Ito N - Search Results

1

External validation of hemoglobin and neutrophil levels as predictors of the effectiveness of ipilimumab plus nivolumab for treating renal cell carcinoma.

Hamamoto S, Tasaki Y, Yamashita S, Furukawa J, Fujita K, Tomida R, Miyake M, Ito N, Iwamoto H, Sugiyama Y, Taguchi K, Yasui T. Hamamoto S, et al. Among authors: ito n. Front Oncol. 2024 Sep 2;14:1400041. doi: 10.3389/fonc.2024.1400041. eCollection 2024. Front Oncol. 2024. PMID: 39286026 Free PMC article.

2

Impact of tumor size on patient survival after radical nephrectomy for pathological T3a renal cell carcinoma.

Sugiyama Y, Yatsuda J, Murakami Y, Ito N, Yamasaki T, Mikami Y, Ogawa O, Kamba T. Sugiyama Y, et al. Among authors: ito n. Jpn J Clin Oncol. 2019 May 1;49(5):465-472. doi: 10.1093/jjco/hyy200. Jpn J Clin Oncol. 2019. PMID: 30793163

3

Association of lung immune prognostic index with survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.

Yamashita S, Hamamoto S, Furukawa J, Fujita K, Takahashi M, Miyake M, Ito N, Iwamoto H, Kohjimoto Y, Hara I. Yamashita S, et al. Among authors: ito n. Jpn J Clin Oncol. 2024 Jun 1;54(6):722-729. doi: 10.1093/jjco/hyae031. Jpn J Clin Oncol. 2024. PMID: 38485656

4

Prognostic impact of FAN score in patients receiving nivolumab plus ipilimumab for metastatic renal cell carcinoma.

Yamashita S, Hamamoto S, Furukawa J, Fujita K, Takahashi M, Miyake M, Ito N, Iwamoto H, Kohjimoto Y, Hara I. Yamashita S, et al. Among authors: ito n. Sci Rep. 2024 May 29;14(1):12398. doi: 10.1038/s41598-024-63403-2. Sci Rep. 2024. PMID: 38811687 Free PMC article.

5

STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma.

Ito N, Eto M, Nakamura E, Takahashi A, Tsukamoto T, Toma H, Nakazawa H, Hirao Y, Uemura H, Kagawa S, Kanayama H, Nose Y, Kinukawa N, Nakamura T, Jinnai N, Seki T, Takamatsu M, Masui Y, Naito S, Ogawa O. Ito N, et al. J Clin Oncol. 2007 Jul 1;25(19):2785-91. doi: 10.1200/JCO.2006.09.8897. J Clin Oncol. 2007. PMID: 17602083

6

Methylation-associated silencing of TU3A in human cancers.

Awakura Y, Nakamura E, Ito N, Kamoto T, Ogawa O. Awakura Y, et al. Among authors: ito n. Int J Oncol. 2008 Oct;33(4):893-9. Int J Oncol. 2008. PMID: 18813805

7

Methylation-associated silencing of SFRP1 in renal cell carcinoma.

Awakura Y, Nakamura E, Ito N, Kamoto T, Ogawa O. Awakura Y, et al. Among authors: ito n. Oncol Rep. 2008 Nov;20(5):1257-63. Oncol Rep. 2008. PMID: 18949430

8

Outcomes of curative nephrectomy against renal cell carcinoma based on a central pathological review of 914 specimens from the era of cytokine treatment.

Ito N, Kojima S, Teramukai S, Mikami Y, Ogawa O, Kamba T. Ito N, et al. Int J Clin Oncol. 2015 Dec;20(6):1161-70. doi: 10.1007/s10147-015-0840-5. Epub 2015 May 16. Int J Clin Oncol. 2015. PMID: 25981949 Free article.

9

Monthly paclitaxel and carboplatin with oral estramustine phosphate in patients with hormone-refractory prostate cancer.

Segawa T, Kamoto T, Kinoshita H, Kunishima Y, Yoshimura K, Ito A, Takahashi T, Higashi S, Nakamura E, Nishiyama H, Ito N, Yamamoto S, Habuchi T, Ogawa O. Segawa T, et al. Among authors: ito a, ito n. Int J Clin Oncol. 2005 Oct;10(5):333-7. doi: 10.1007/s10147-005-0513-x. Int J Clin Oncol. 2005. PMID: 16247660 Clinical Trial.

10

Influence of body mass index on prognosis of Japanese patients with renal cell carcinoma.

Awakura Y, Nakamura E, Ito N, Yamasaki T, Kamba T, Kamoto T, Ogawa O. Awakura Y, et al. Among authors: ito n. Urology. 2007 Jul;70(1):50-4. doi: 10.1016/j.urology.2007.03.034. Urology. 2007. PMID: 17656207

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,638 results

Search Page

Filters